1. Tumor promoting capacity of polymorphonuclear myeloid‐derived suppressor cells and their neutralization
- Author
-
Christopher Groth, Jochen Utikal, Annina Kurzay, Feyza Gül Özbay, Viktor Umansky, Vera Petrova, Peter Altevogt, Samantha Lasser, and Rebekka Weber
- Subjects
Cancer Research ,Carcinogenesis ,Neutrophils ,T-Lymphocytes ,medicine.medical_treatment ,Cell ,Population ,Biology ,law.invention ,Metastasis ,Cancer immunotherapy ,law ,Neoplasms ,Tumor Microenvironment ,medicine ,Animals ,Humans ,education ,education.field_of_study ,Myeloid-Derived Suppressor Cells ,Cancer ,Immunotherapy ,medicine.disease ,Killer Cells, Natural ,medicine.anatomical_structure ,Oncology ,Myeloid-derived Suppressor Cell ,Cancer research ,Suppressor - Abstract
Myeloid-derived suppressor cells (MDSC) represent a highly immunosuppressive population that expands in tumor bearing hosts and inhibits both T and NK cell anti-tumor effector functions. Among MDSC subpopulations, the polymorphonuclear (PMN) one is gaining increasing interest since it is a predominant MDSC subset in most cancer entities and inherits unique properties to facilitate metastatic spread. In addition, further improvement in distinguishing PMN-MDSC from neutrophils has contributed to the design of novel therapeutic approaches. In this review, we summarize the current view on the origin of PMN-MDSC and their relation to classical neutrophils. Furthermore, we outline the metastasis promoting features of these cells and promising strategies of their targeting to improve the efficacy of cancer immunotherapy. This article is protected by copyright. All rights reserved.
- Published
- 2021